AbstractThere have been many treatment modalities used for the therapy of cutaneous leishmaniasis. Although treatment need not be given for cosmetically insignificant lesions, which are often self-limited, therapy is usually indicated for larger, cosmetically significant and disfiguring lesions, and lesions which progress. This review summarizes the published evidence in support of the numerous therapeutic options that have been employed for cutaneous leishmaniasis
Parenteral pentavalent antimonials remain the standard therapy for cutaneous leishmaniasis. More eff...
Sixty-seven patients, 19 females and 48 males, 4-66 years old, suffering from lesions of cutaneous l...
Progress with the treatment of cutaneous leishmaniasis (CL) has been hampered by inconsistent method...
Cutaneous leishmaniasis has been endemic since decades. Millions of cases are reported worldwide spe...
AbstractThere have been many treatment modalities used for the therapy of cutaneous leishmaniasis. A...
Diagnosis and therapy of cutaneous leishmaniasis (CL) can be difficult due to the variability of the...
Leishmaniasis is endemic in 88 countries on five continents. There are 1–1.5 million cases of cutane...
Cutaneous leishmaniasis (CL) and mucocutaneous leishmaniasis (ML) show clinical spectra that can ran...
Leishmaniasis including Cutaneous, mocucutaneous and Visceral forms of clinical syndromes is one of ...
Introduction: Most drugs being used for cutaneous leishmania treatment are still non well effective,...
Leishmaniasis is an important public health problem in the Americas. A Cochrane review published in ...
Leishmaniasis is endemic in 88 countries on five continents. There are 1–1.5 million cases of cutane...
Mucocutaneous is an infection caused by a single celled parasite transmitted by sand fly bites. Ther...
The current drugs available for the treatment of cutaneous leishmaniasis (CL) often cause several ad...
Cutaneous leishmaniasis is a parasitic disease occurring throughout the Americas from Texas to Argen...
Parenteral pentavalent antimonials remain the standard therapy for cutaneous leishmaniasis. More eff...
Sixty-seven patients, 19 females and 48 males, 4-66 years old, suffering from lesions of cutaneous l...
Progress with the treatment of cutaneous leishmaniasis (CL) has been hampered by inconsistent method...
Cutaneous leishmaniasis has been endemic since decades. Millions of cases are reported worldwide spe...
AbstractThere have been many treatment modalities used for the therapy of cutaneous leishmaniasis. A...
Diagnosis and therapy of cutaneous leishmaniasis (CL) can be difficult due to the variability of the...
Leishmaniasis is endemic in 88 countries on five continents. There are 1–1.5 million cases of cutane...
Cutaneous leishmaniasis (CL) and mucocutaneous leishmaniasis (ML) show clinical spectra that can ran...
Leishmaniasis including Cutaneous, mocucutaneous and Visceral forms of clinical syndromes is one of ...
Introduction: Most drugs being used for cutaneous leishmania treatment are still non well effective,...
Leishmaniasis is an important public health problem in the Americas. A Cochrane review published in ...
Leishmaniasis is endemic in 88 countries on five continents. There are 1–1.5 million cases of cutane...
Mucocutaneous is an infection caused by a single celled parasite transmitted by sand fly bites. Ther...
The current drugs available for the treatment of cutaneous leishmaniasis (CL) often cause several ad...
Cutaneous leishmaniasis is a parasitic disease occurring throughout the Americas from Texas to Argen...
Parenteral pentavalent antimonials remain the standard therapy for cutaneous leishmaniasis. More eff...
Sixty-seven patients, 19 females and 48 males, 4-66 years old, suffering from lesions of cutaneous l...
Progress with the treatment of cutaneous leishmaniasis (CL) has been hampered by inconsistent method...
DOI
Add to ORKG